Hepion Pharmaceuticals Inc (HEPA):企業の財務・戦略的SWOT分析

◆英語タイトル:Hepion Pharmaceuticals Inc (HEPA) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH503409FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年4月
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD600 ⇒換算¥76,800見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD900 ⇒換算¥115,200見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Hepion Pharmaceuticals Inc (Hepion) formerly known as ContraVir Pharmaceuticals Inc, is a biopharmaceutical company that offers development and commercialization of targeted antiviral therapies. The company provides pipeline product such as TXL, potent prodrug of antiviral tenofovir and CRV431 cyclophilin inhibitor that increases its potency and selective index against HBV. It products are used for the treatment of chronic hepatitis B and shingles. Hepion serves atients and healthcare professionals by developing differentiated therapeutic products. The company operates in the US. Hepion is headquartered in Edison, New Jersey, the US.

Hepion Pharmaceuticals Inc Key Recent Developments

Mar 22,2021: Hepion Pharmaceuticals Announces Presentation and Panel Participation at the Benzinga Global Biotech Small Cap Conference
Oct 05,2020: Hepion Pharmaceuticals introduces proprietary A.I. platform for drug development & announces creation of clinical pharmacology analytics team
Jun 10,2020: Hepion Pharmaceuticals welcomes industry veteran and drug development expert, Dr. Peter Wijngaard, to its Board of Directors
Apr 13,2020: Hepion Pharmaceuticals receives loan under Paycheck Protection Program

This comprehensive SWOT profile of Hepion Pharmaceuticals Inc provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

This company report forms part of GlobalData’s ‘Profile on Demand’ service, covering over 50,000 of the world’s leading companies. Once purchased, GlobalData’s highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of Hepion Pharmaceuticals Inc including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. (excluding weekends).

The profile contains critical company information including*,

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note*: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include,

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

【レポートの目次】

Table of Contents

Section 1 – About the Company

Hepion Pharmaceuticals Inc – Key Information
Hepion Pharmaceuticals Inc – Overview
Hepion Pharmaceuticals Inc – Key Employees
Hepion Pharmaceuticals Inc – Key Employee Biographies
Hepion Pharmaceuticals Inc – Key Operational Heads
Hepion Pharmaceuticals Inc – Major Products and Services
Hepion Pharmaceuticals Inc – History
Hepion Pharmaceuticals Inc – Company Statement
Hepion Pharmaceuticals Inc – Locations And Subsidiaries
Hepion Pharmaceuticals Inc
Head Office
Other Locations & Subsidiaries

Section 2 – Company Analysis

Hepion Pharmaceuticals Inc – Business Description
Hepion Pharmaceuticals Inc – Corporate Strategy
Hepion Pharmaceuticals Inc – SWOT Analysis
SWOT Analysis – Overview
Hepion Pharmaceuticals Inc – Strengths
Hepion Pharmaceuticals Inc – Weaknesses
Hepion Pharmaceuticals Inc – Opportunities
Hepion Pharmaceuticals Inc – Threats
Hepion Pharmaceuticals Inc – Key Competitors

Section 3 – Company Financial Performance Charts

Hepion Pharmaceuticals Inc – Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts

Section 4 – Appendix

Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

Note*: Some sections may be missing if data is unavailable for the company

List of Tables

Hepion Pharmaceuticals Inc, Key Information
Hepion Pharmaceuticals Inc, Key Ratios
Hepion Pharmaceuticals Inc, Share Data
Hepion Pharmaceuticals Inc, Major Products and Services
Hepion Pharmaceuticals Inc, History
Hepion Pharmaceuticals Inc, Key Employees
Hepion Pharmaceuticals Inc, Key Employee Biographies
Hepion Pharmaceuticals Inc, Key Operational Heads
Hepion Pharmaceuticals Inc, Other Locations
Hepion Pharmaceuticals Inc, Subsidiaries
Hepion Pharmaceuticals Inc, Key Competitors
Hepion Pharmaceuticals Inc, SWOT Analysis
Hepion Pharmaceuticals Inc, Ratios based on current share price
Hepion Pharmaceuticals Inc, Annual Ratios
Hepion Pharmaceuticals Inc, Interim Ratios
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[Hepion Pharmaceuticals Inc (HEPA):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Hess Corporation:企業の戦略・SWOT・財務情報
    Hess Corporation - Strategy, SWOT and Corporate Finance Report Summary Hess Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Aker Solutions ASA (AKSO):企業の財務・戦略的SWOT分析
    Aker Solutions ASA (AKSO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Federal Signal Corp (FSS):企業の財務・戦略的SWOT分析
    Federal Signal Corp (FSS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Aveda Transportation and Energy Services Inc (AVE):石油・ガス:M&Aディール及び事業提携情報
    Summary Aveda Transportation and Energy Services Inc (Aveda), formerly Phoenix Oilfield Hauling Inc is an oilfield service provider that offers energy transportation and other energy related services. The company provides specialized transportation services and equipment for drilling, exploration, d …
  • SeQuent Scientific Ltd (512529):企業の財務・戦略的SWOT分析
    Summary SeQuent Scientific Ltd (SeQuent) is a pharmaceutical company that develops and manufactures animal health API, life science and industrial products. The company offers products such as aciclovir sodium, albendazole, artemether, artesunate, amyl meta cresol, citicoline sodium and dihydroartem …
  • Coherus BioSciences Inc (CHRS):製薬・医療:M&Aディール及び事業提携情報
    Summary Coherus BioSciences Inc (Coherus) is a biosimilar platform company that develops and commercializes biosimilar drugs. The company’s pipeline product candidates include CHS-1701, an pegfilgrastim used to treat febrile neutropenia; CHS-0214, is an etanercept biosimilar candidate which is used …
  • GE Energy:戦略・SWOT・企業財務分析
    GE Energy - Strategy, SWOT and Corporate Finance Report Summary GE Energy - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • AngloGold Ashanti Ltd:企業の戦略・SWOT・財務情報
    AngloGold Ashanti Ltd - Strategy, SWOT and Corporate Finance Report Summary AngloGold Ashanti Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Luxembourg Institute of Health:製薬・医療:M&Aディール及び事業提携情報
    Summary Luxembourg Institute of Health (LIH), formerly Centre de Recherche Public de la Sante is a biomedical research organisation that offers pre-clinical and clinical research in the areas of biomedicine and healthcare. The organization offers research under various departments such as infection …
  • Nilkamal Ltd:企業の戦略・SWOT・財務情報
    Nilkamal Ltd - Strategy, SWOT and Corporate Finance Report Summary Nilkamal Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Spinal Elements Inc:医療機器:M&Aディール及び事業提携情報
    Summary Spinal Elements Inc (Spinal Elements), formerly Quantum Orthopedics Inc, a subsidiary of Spinal Elements, is a medical device manufacturing company that manufactures spinal implants and instruments. The company provides products such as cervical implant systems, anterior cervical plate syste …
  • Auris Medical Holding AG (EARS):企業の財務・戦略的SWOT分析
    Auris Medical Holding AG (EARS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Actelion Pharmaceuticals Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Actelion Pharmaceuticals Ltd (Actelion), subsidiary of Johnson & Johnson is a biopharmaceutical company, which discovers, develops and commercializes innovative treatments for diseases with considerable unmet medical needs. The company focuses on the development of treatments for pulmonary a …
  • Enel Russia (ENRU):電力:M&Aディール及び事業提携情報
    Summary Enel Russia, a subsidiary of Enel Investment Holding BV, is an energy utility. It produces electricity and thermal energy. The company generates electricity using coal, gas and fuel oil sources. Enel Russia owns and operates Konakovskaya GRES, Nevinnomysskaya GRES, Reftinskaya GRES and Sredn …
  • PendoPharm Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary PendoPharm Inc (PendoPharm), a subsidiary of Pharmascience Inc, is a healthcare company that provides production and commercialization of a wide range of drugs. The company provides products such as spans prescription drugs, over-the-counter and behind-the-counter products, among others. Its …
  • Hoag Hospital Foundation:企業の戦略的SWOT分析
    Hoag Hospital Foundation - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • Anika Therapeutics Inc (ANIK)-製薬・医療分野:企業M&A・提携分析
    Summary Anika Therapeutics Inc (Anika) is a medical technology company which develops, manufactures, and markets therapeutic products for tissue protection, repair and regeneration. It offers solutions for orthobiologics, dermal, ophthalmic, surgical and veterinary applications. Its major products i …
  • London Stock Exchange Group Plc:戦略・SWOT・企業財務分析
    London Stock Exchange Group Plc - Strategy, SWOT and Corporate Finance Report Summary London Stock Exchange Group Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Amey Plc:企業の戦略的SWOT分析
    Amey Plc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Thi …
  • Xintela AB (XINT):企業の財務・戦略的SWOT分析
    Summary Xintela AB (Xintela) is a biomedical company that develops treatment for cartilage damage and brain tumors. The company’s technology includes Xinmark, a patented marker technology developed to identify and select certain types of tumor cells, which can develop into cartilage cells. It also o …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆